TW221292B - - Google Patents

Info

Publication number
TW221292B
TW221292B TW081107894A TW81107894A TW221292B TW 221292 B TW221292 B TW 221292B TW 081107894 A TW081107894 A TW 081107894A TW 81107894 A TW81107894 A TW 81107894A TW 221292 B TW221292 B TW 221292B
Authority
TW
Taiwan
Prior art keywords
alkyl
phenyl
optionally substituted
hydroxy
carboxy
Prior art date
Application number
TW081107894A
Other languages
English (en)
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919121358A external-priority patent/GB9121358D0/en
Priority claimed from GB929213058A external-priority patent/GB9213058D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Application granted granted Critical
Publication of TW221292B publication Critical patent/TW221292B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW081107894A 1991-10-09 1992-10-05 TW221292B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919121358A GB9121358D0 (en) 1991-10-09 1991-10-09 Pharmaceutical compounds
GB929213058A GB9213058D0 (en) 1992-06-19 1992-06-19 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
TW221292B true TW221292B (zh) 1994-02-21

Family

ID=26299655

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081107894A TW221292B (zh) 1991-10-09 1992-10-05

Country Status (22)

Country Link
US (1) US5284868A (zh)
EP (1) EP0537949B1 (zh)
JP (1) JPH05194477A (zh)
KR (1) KR100228841B1 (zh)
CN (1) CN1034938C (zh)
AT (1) ATE167859T1 (zh)
AU (1) AU658003B2 (zh)
CA (1) CA2079428A1 (zh)
CZ (1) CZ281688B6 (zh)
DE (1) DE69226060T2 (zh)
DK (1) DK0537949T3 (zh)
ES (1) ES2117035T3 (zh)
FI (1) FI924551A (zh)
HU (1) HU218916B (zh)
IL (1) IL103356A (zh)
MX (1) MX9205714A (zh)
MY (1) MY111368A (zh)
NO (1) NO301587B1 (zh)
NZ (1) NZ244627A (zh)
PH (1) PH30659A (zh)
RU (1) RU2071472C1 (zh)
TW (1) TW221292B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
EP0599514A3 (en) * 1992-11-18 1994-07-06 Lilly Industries Ltd Pyranoquinoline derivatives as inhibitors of cell proliferation.
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
EP0619314A1 (en) * 1993-04-09 1994-10-12 Eli Lilly And Company 4-Phenyl-4H- naphtho(2,1-b)pyran derivatives and their pharmaceutical use
WO1995008289A2 (en) * 1993-09-16 1995-03-30 Scimed Life Systems, Inc. Percutaneous repair of cardiovascular anomalies and repair compositions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
CN1219872A (zh) * 1996-05-24 1999-06-16 血管技术药物公司 治疗或预防身体通道疾病的组合物和方法
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
ATE260269T1 (de) 1999-11-05 2004-03-15 Cytovia Inc Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung
EP1392683B1 (en) * 2001-05-16 2009-12-02 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and their use as anticancer agents
EP1392283A4 (en) 2001-05-16 2004-10-20 Cytovia Inc COUMARINS AND SUBSTITUTED QUINOLINES USED AS CASPASE ACTIVATORS
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1513515A2 (en) * 2002-05-16 2005-03-16 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1509515A4 (en) * 2002-05-16 2006-07-05 Cytovia Inc SUBSTITUTED 4-ARYL-4H-PYRROLO 2,3-H | CHROMENES AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THEIR USE
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
NZ553688A (en) * 2004-09-09 2011-05-27 Florey Howard Inst Enzyme inhibitors for the inhibition of insulin-regulated aminopeptidase
EP2532388A3 (en) * 2005-02-16 2013-03-06 Md Bioalpha Co., Ltd. Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
US20080183282A1 (en) * 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
US8263775B2 (en) 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
EA015364B1 (ru) * 2009-03-18 2011-06-30 Учреждение Российской Академии Наук Институт Элементоорганических Соединений Им. А.Н. Несмеянова Ран (Инэос Ран) 6,6'-диизопропил-8,8'-диметил-2,2'-динитро-3,3'-бис(трифторметил)- 3н,3'н-[9,9']ди[бензо(f)хроменил]-5,10,5',10'-тетраол, обладающий противоопухолевой и противогрибковой активностью, и способ его получения
WO2012062901A2 (en) * 2010-11-12 2012-05-18 Deutsches Krebsforschungszentrum (Dkfz) Chromene derivatives and their analoga as wnt pathway antagonists
WO2013070998A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU724509A1 (ru) * 1978-09-21 1980-03-30 Пермский государственный фармацевтический институт Способ получени 2-ароил-3н- нафто 2,1-в пиранонов-3
US5232942A (en) * 1988-04-14 1993-08-03 Yamanouchi Pharmaceutical Co., Ltd. Q-2819 substance and the use thereof

Also Published As

Publication number Publication date
EP0537949A1 (en) 1993-04-21
NO923910D0 (no) 1992-10-08
KR100228841B1 (ko) 1999-11-01
CZ281688B6 (cs) 1996-12-11
ES2117035T3 (es) 1998-08-01
CA2079428A1 (en) 1993-04-10
PH30659A (en) 1997-09-16
NO923910L (no) 1993-04-13
MX9205714A (es) 1993-04-01
CZ303592A3 (en) 1993-12-15
MY111368A (en) 1999-12-31
IL103356A0 (en) 1993-03-15
EP0537949B1 (en) 1998-07-01
DK0537949T3 (da) 1999-02-15
IL103356A (en) 1998-02-22
HU218916B (hu) 2000-12-28
AU2621692A (en) 1993-04-22
NZ244627A (en) 1994-12-22
FI924551A0 (fi) 1992-10-08
HUT62281A (en) 1993-04-28
KR930007931A (ko) 1993-05-20
JPH05194477A (ja) 1993-08-03
DE69226060T2 (de) 1998-11-19
DE69226060D1 (de) 1998-08-06
NO301587B1 (no) 1997-11-17
ATE167859T1 (de) 1998-07-15
CN1073437A (zh) 1993-06-23
AU658003B2 (en) 1995-03-30
RU2071472C1 (ru) 1997-01-10
CN1034938C (zh) 1997-05-21
US5284868A (en) 1994-02-08
FI924551A (fi) 1993-04-10
HU9203183D0 (en) 1992-12-28

Similar Documents

Publication Publication Date Title
TW221292B (zh)
CO5150224A1 (es) Compuestos de triazol y su utilizacion
GB0226593D0 (en) Compounds
DK0765314T3 (da) Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer
NO983099D0 (no) Nye retrovirale proteasehemmere
FI913782A (fi) Isoxazolderivat.
ES2091359T3 (es) Nuevo compuesto peptidico y un procedimiento para su preparacion.
DK0641325T3 (da) Inhibitorer af retroviral protease
FI930977A0 (fi) Taxanderivat, deras framstaellning och onkologiska anvaendning
ATE261960T1 (de) Sulfonamide mit elastase inhibierender wirkung
MY109777A (en) Pharmaceutical compounds therewith
DK0743938T3 (da) Substituerede spiroforbindelser til behandling af inflammation
DK0639173T3 (da) Visse 2- (2'-methyl-3', 4'-trisubstitueret benzoyl) -1,3-cyklohexandioner
DK0417746T3 (da) N-Azabicyclo(3.3.0)octanamider af aromatiske syrer
TR199902387T2 (xx) Antibakteriyal ornat�lm�� 7-a�ilamino-3-(Metilhidrazono) Metil-Sefalosporinler ve ara �r�nleri.
ES8303438A1 (es) Un procedimiento para la preparacion de perfluoroamidas
ID836B (id) Alat pelindung tekanan arus
MX9204939A (es) Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
TH17774EX (th) อนุพันธ์ 1,3-ออกซาซิน-4-โอนชนิดใหม่ สารฆ่าวัชพืชที่มีอนุพันธ์เหล่านี้และสารมัธยันตร์สำหรับการเตรียอนุพันธ์เหล่านี้
CO5210866A1 (es) Inhibidores de cinasas, de pirrolotriazina
IT1162465B (it) Procedimento per proteggere materiali cheratinici da insetti ed agenti nonche' composti barbiturici per esso
EP0588608A3 (en) Tricyclic compounds and pharmaceutical compositions containing them